Univasc® also known as moexipril, belongs to a group of antihypertensive medications referred to as angiotensin-converting enzyme inhibitors (ACE) inhibitors. The medication acts by preventing the conversion of certain chemicals that contribute to vasoconstriction. Health care providers often prescribe Univasc® in conjunction with thiazide diuretic medications in order to eliminate excess body fluid. Individuals typically take the medication once daily and monitor blood pressure for overall effectiveness of treatment.
ACE inhibitors react to the renin-angiotensin-aldosterone chemicals in the body. These chemicals and enzymes usually regulate blood pressure by decreasing or increasing the amount of fluid circulation by causing vasoconstriction. The added vascular pressure forces excess fluid to filter through the kidneys. The body continues to use these mechanisms despite possible physical changes, such as vascular walls losing elasticity or becoming unusually thick. Blood also might thicken abnormally or increase in volume.
These physical changes along with normal bodily processes contribute to hypertension. By preventing the chemical conversions that cause vasoconstriction, Univasc® relaxes blood vessels and reduces the pressure of circulating fluid, thus decreasing blood pressure. Excess circulating blood or fluid affects blood pressure by exerting pressure on vessel walls. When the body cannot naturally eliminate this fluid because of abnormal sodium levels or other failed mechanisms, diuretics usually assist by redirecting additional flow through the kidneys. The combined effects of Univasc® and diuretics generally provide adequate blood pressure treatment.
Health care providers generally prescribe Univasc® in daily dosages of 7.5 to 30 milligrams, and patients usually take the medication on an empty stomach to ensure proper absorption. Physicians typically adjust the dosage of the blood pressure medication based on results. Some individuals might require higher dosages or divided dosages for more effective high blood pressure relief. Univasc® and other ACE inhibitors are generally not as effective in controlling hypertension in persons belonging to the African-American community.
As medications are typically metabolized by the liver and or the kidneys, individuals who have diseases related to these organs are more prone to adverse effects. Anaphylactic reactions can occur, but cough or dizziness are the most frequently reported side effects that patients experience when taking this medication. Persons might also experience abdominal discomfort accompanied by diarrhea. Univasc® can also interfere with the processes contributing to the development of granulocytes, the white blood cells responsible for natural immune responses.
Some individuals report flu-like and upper respiratory symptoms, which include fatigue, headaches, muscle aches and sinus infections. In rare instances, patients suffer a condition known as angioedema. Unusual swelling may occur in the extremities or in the face and neck, posing a possible danger of airway obstruction.
